Latest Articles about IND

Market Trends Offer Opportunities for FPMI - Analyst Blog

Brian Marckx — Mon, 20 May 2013 21:01:01 Z

FluoroPharma Medical, Inc. (OTC BB:FPMI) seeks to develop breakthrough molecular imaging agents for positron emission tomography (PET) to fulfill critical medical needs. The company's products

Wider-than-Expected Loss at Endocyte - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 22:18:01 Z

Endocyte, Inc. ( ECYT ) reported first quarter 2013 net loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than the year-ago loss

Loss Widens at Momenta - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 17:57:19 Z

Momenta Pharmaceuticals Inc. ( MNTA ) reported first quarter 2013 net loss per share of 48 cents, wider than the Zacks Consensus Estimate of a loss of 43 cents and the year-ago loss of 10

AZN/BIND Therapeutics Ink Deal - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 03:11:20 Z

AstraZeneca ( AZN ) recently announced that it has entered into an agreement with BIND Therapeutics for the development and commercialization of Accurin (a cancer nanomedicine). As per

ImmunoGen to Focus on Pipeline - Analyst Blog

Zacks Equity Research — Tue, 16 Apr 2013 03:05:01 Z

ImmunoGen Inc. ( IMGN ) recently provided an update on its pipeline and maintained its outlook for fiscal year 2013 (ending June 30) at its recently held Analyst & Investor Day.

ADC Data from Seattle Genetics - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 02:08:01 Z

Seattle Genetics Inc. ( SGEN ) recently presented data on its antibody-drug conjugate (ADC) candidates at the annual meeting of the American Association for Cancer Research (AACR).

Idenix Reports In-Line 4Q Loss - Analyst Blog

Zacks Equity Research — Fri, 01 Mar 2013 20:08:01 Z

Idenix Pharmaceuticals' ( IDIX ) loss of 17 cents per share in the fourth quarter of 2012 was a penny below the year-ago loss and in-line with the Zacks Consensus Estimate. The company's

Loss at MNTA Narrower than Expected - Analyst Blog

Zacks Equity Research — Wed, 20 Feb 2013 02:29:01 Z

Momenta Pharmaceuticals Inc. ( MNTA ) reported fourth quarter 2012 net loss per share of 35 cents, narrower than the Zacks Consensus Estimate of a loss of 41 cents, but wider than the

Pipeline Setback for Idenix - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 03:10:01 Z

Idenix Pharmaceuticals, Inc. ( IDIX ) recently announced that the company has decided to discontinue its clinical development program for IDX184. IDX184 is a nucleotide polymerase

Pipeline Progress at Endocyte - Analyst Blog

Zacks Equity Research — Fri, 01 Feb 2013 04:30:01 Z

Endocyte Inc. ( ECYT ) recently announced that its oncology candidate, EC0652, achieved key objectives in a phase 0 study. Endocyte is developing the candidate as a treatment of patients

Wider Loss at ImmunoGen - Analyst Blog

Zacks Equity Research — Mon, 28 Jan 2013 19:16:01 Z

ImmunoGen Inc. ( IMGN ) reported second quarter fiscal 2013 adjusted loss of 29 cents per share, wider than both the Zacks Consensus Estimate of a loss of 24 cents and the year-ago loss of

Infinity Provides Pipeline Update - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 22:20:01 Z

Infinity Pharmaceuticals Inc. ( INFI ) recently provided an update on its pipeline and issued its guidance for 2013. The company expects to report data from both its development programs -

ING Group, N.V. (IND) Ex-Dividend Date Scheduled for November 28, 2012

NASDAQ.com News — Mon, 26 Nov 2012 19:00:03 Z

ING Group, N.V. ( IND ) has announced an ex-dividend date of November 28, 2012 and a cash dividend payment of $0.4406 per share scheduled for December 15, 2012. Shareholders who purchased IND

Loss at Elan Wider than Expected - Analyst Blog

Zacks Equity Research — Thu, 25 Oct 2012 20:20:01 Z

Elan Corporation 's ( ELN ) loss of 12 cents per share (excluding special items) for the third quarter of 2012 was wider than the Zacks Consensus Estimate of a loss of 8 cents per share.

IND Submission by Synergy Pharma - Analyst Blog

Zacks Equity Research — Tue, 18 Sep 2012 01:34:01 Z

Synergy Pharmaceuticals Inc. ( SGYP ) recently announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its inflammatory